Bionomics Limited (BNOEF) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Eastwood, SA, Australia. The current CEO is Spyridon Papapetropoulos.
BNOEF has IPO date of 2014-06-24, listed on the Other OTC, a market capitalization of $8.81M.
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
